Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Michael Schnekenburger

Senior Scientist

Luxembourg Institute of Health

Luxembourg

Research Interests

Explore related searches

Professors in Luxembourg Professors in Biochemistry Biochemistry professors in Luxembourg

Articles (9)

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (6)

Johan Wouters

Full professor

University of Namur

BELGIUM

View details

Bernard Pirotte

University of Liege

BELGIUM

View details

Sarah Skuli

Assistant Professor

University of Cincinnati

UNITED STATES

View details

Marc Diederich

Seoul National University

SOUTH KOREA

View details

Hyoung Jin Kang

Professor

Seoul National University Hospital

SOUTH KOREA

View details

Steffen Boettcher

Assistant professor

University Hospital of Zurich

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Schnekenburger

Research Interests

Explore related searches

Articles (9)

Dual Beclin 1 post-translational reprogramming by BCR-ABL and HDAC6 inhibition disables autophagic flux and overcomes CML resistance

Preparation and pharmacological characterization of the enantiomers of the anticancer agent R/S-N-3-cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea: Identification of the R-enantiomer as the active eutomer

Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia

TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia

Tetrahydrobenzimidazole TMQ0153 targets OPA1 and restores drug sensitivity in AML via ROS-induced mitochondrial metabolic reprogramming

New rhodol-sulforaphane conjugates as innovative isothiocyanate-based cytotoxic agents for cancer cells

HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics

Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy

Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation

Collaborators (6)

Johan Wouters

Bernard Pirotte

Sarah Skuli

Marc Diederich

Hyoung Jin Kang

Steffen Boettcher

Make your next move.